Clinical trial
3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid…
NCT00079014 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00079014 |
|---|---|
| Title | 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors |
| Official title | A Phase I Study of Triapine® in Combination With Doxorubicin in Refractory Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | triapine, doxorubicin hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 36 |
| Start date | Jan 1, 2004 |
| Primary completion | Jul 1, 2008 |
| First posted | Mar 9, 2004 |
| Last update posted | May 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: